p38 MAP kinase: a convergence point in cancer therapy.

James M Olson, Andrew R Hallahan

Journal: Trends in molecular medicine 2004;10(3):125-9

PMID: 15102355

Full Text on Elsevier Science View on PubMed

Abstract

Recent studies show that activation of p38 mitogen-activated protein kinase (MAPK) results in cancer cell apoptosis initiated by retinoids, cisplatin and other chemotherapeutic agents. The observation that divergent therapies act through a common signal transduction pathway raises the possibility of developing new anti-cancer agents that lack the side-effects caused by events upstream of p38 MAPK. Here, we review p38-MAPK-mediated tumor cell apoptosis and implications for cancer therapeutics.

Address: Fred Hutchinson Cancer Research Center, and Department of Pediatrics, University of Washington, Seattle, WA, USA. [email protected]

DOI: 10.1016/j.molmed.2004.01.007

Link outs

Free resources

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1471...

MeSH Terms: Antineoplastic Agents, Apoptosis, Cisplatin, Drug Design, Enzyme Activation, Humans, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases, Neoplasms, Retinoids, p38 Mitogen-Activated Protein Kinases